M&A Deal Summary

Alexion Pharmaceuticals Acquires Synageva BioPharma

On May 6, 2015, Alexion Pharmaceuticals acquired life science company Synageva BioPharma for 8.4B USD

Acquisition Highlights
  • This is Alexion Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is Alexion Pharmaceuticals’ largest (disclosed) transaction.
  • This is Alexion Pharmaceuticals’ 3rd transaction in the United States.
  • This is Alexion Pharmaceuticals’ 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2015-05-06
Target Synageva BioPharma
Sector Life Science
Buyer(s) Alexion Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 8.4B USD
Advisor(s) Goldman Sachs (Financial)
Sullivan & Cromwell
Ropes & Gray (Legal)

Target

Synageva BioPharma

Lexington, Massachusetts, United States
Synageva BioPharma Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's pipeline consists of protein therapeutic programs for rare diseases with unmet medical need which are currently at various stages of development.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alexion Pharmaceuticals

Boston, Connecticut, United States
Category Company
Founded 1992
Sector Life Science
Employees3,082
Revenue 6.1B USD (2020)
DESCRIPTION

Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.

DEAL STATS #
Overall 4 of 9
Sector (Life Science) 3 of 8
Type (Add-on Acquisition) 4 of 9
State (Massachusetts) 2 of 4
Country (United States) 3 of 7
Year (2015) 1 of 1
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-12-28 Enobia Pharma

Montreal, Quebec, Canada

Enobia Pharma focuses on the development of therapies for patients with genetic metabolic bone disorders. Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. Enobia is based in Montreal, Quebec.

Buy $1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-04-11 Wilson Therapeutics AB

Stockholm, Sweden

Wilson Therapeutics AB is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ product, WTX101, is in Phase 3 development as a novel treatment for Wilson disease.

Buy $855M
Mergr

Product

Company

Legal